RedHill Biopharma Ltd. - 20-F Annual Report Summary (Fiscal Year Ended Dec 31, 2016)
Business Context and Reporting Period
Company: RedHill Biopharma Ltd.
Reporting Period: Fiscal year ended December 31, 2016.
Jurisdiction: Israel (incorporated), listed on NASDAQ Capital Market (ADS) and Tel Aviv Stock Exchange (Ordinary Shares).
Business Model: A specialty biopharmaceutical company focused on developing and commercializing late clinical-stage, orally-administered small molecule drugs for gastrointestinal (GI), inflammatory diseases, and cancer. The company has no history of significant commercial revenue and relies on equity financing and licensing deals.
Key Financial Metrics
| Metric (in thousands USD) | 2016 | 2015 |
|---|---|---|
| Revenues | $101 | $3 |
| Research & Development Expenses | $25,241 | $17,771 |
| General, Administrative & Business Dev. Expenses | $5,403 | $4,134 |
| Operating Loss | $(30,543) | $(22,002) |
| Net Loss | $(29,370) | $(21,090) |
| Cash and Short-Term Investments | $66,154 | $58,138 |
| Working Capital | $62,459 | $54,996 |
| Total Liabilities | $11,511 | $6,751 |
| Accumulated Deficit | $(89,635) | $(61,944) |
Note: The company reported negligible revenue in 2016, primarily from licensing RIZAPORT. There is no debt listed in the selected financial data, though the company has significant contractual obligations for future milestone payments and royalties.
Material Changes vs. Prior Period
- Revenue: Increased from $3,000 in 2015 to $101,000 in 2016, driven by licensing revenues related to RIZAPORT (approved in Germany, licensed for Spain and South Korea).
- Operating Expenses: Operating loss widened by approximately 39% to $30.5 million. R&D expenses increased by 42% ($7.4 million) due to ongoing Phase III trials for RHB-104 (Crohn's disease), BEKINDA (gastroenteritis/IBS-D), and YELIVA (oncology).
- Liquidity: Cash and short-term investments increased by $8 million to $66.2 million, bolstered by a December 2016 underwritten public offering and concurrent registered direct offering raising approximately $39.4 million in gross proceeds.
- Strategic Shift: Entered a Co-Promotion Agreement in December 2016 with Concordia International Corp. to promote Donnatal (a legacy GI drug) in the U.S., marking a move toward building independent commercialization capabilities.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring significant operating losses as it advances clinical trials. The company does not anticipate significant revenues or profits in the near future. Future capital requirements depend on clinical trial success, regulatory approvals, and the ability to commercialize Donnatal or out-license candidates.
Key Risks and Contingencies:
- Regulatory Uncertainty (Donnatal): Donnatal is a pre-1962 drug under the FDA's Drug Efficacy Study Implementation (DESI) program. It is not FDA-approved for efficacy, and the FDA could initiate proceedings to remove it from the market, which would materially impact the company's commercialization strategy.
- Clinical Trial Risks: Failure of ongoing Phase III trials (RHB-104, BEKINDA) or delays in regulatory submissions (RIZAPORT NDA resubmission planned for Q3 2017) could delay revenue generation.
- Liquidity Needs: Despite $66.2 million in cash, management states current resources are insufficient to complete development of all therapeutic candidates. Additional equity or debt financing will be required, potentially causing dilution.
- Third-Party Reliance: The company relies on third parties for manufacturing (e.g., IntelGenx for RIZAPORT, Concordia for Donnatal) and clinical trials. Supply chain disruptions or partner failures pose significant risks.
Investor Verification Checklist
- Donnatal Regulatory Status: Verify the current status of the FDA DESI hearing regarding Donnatal and any recent communications from the FDA regarding its market clearance.
- Cash Burn Rate: Assess the runway provided by the $66.2 million cash balance against the projected costs of the RHB-104 Phase III trial and the new Donnatal promotion activities.
- RIZAPORT NDA Resubmission: Monitor the timeline and FDA response to the planned Q3 2017 resubmission of the New Drug Application for RIZAPORT in the U.S.
- Donnatal Commercialization: Evaluate the terms of the Co-Promotion Agreement with Concordia, specifically the revenue split and Concordia's responsibility for manufacturing and supply.
- Intellectual Property: Review the patent expiration dates for key assets (e.g., RHB-105 patents expiring 2019 vs. 2034) and the status of pending applications.